The health information company that sells information about doctors, hospitals and drugs, Alibaba Health, is set to lose millions of dollars in a US class action lawsuit over its anti-viruses.

In the lawsuit filed in San Francisco federal court on Monday, a class of nearly 400,000 consumers and their attorneys say the health information giant, which was bought by Amazon in 2012, is guilty of anticompetitive conduct that harms their business.

The suit alleges that in the last five years, Alibaba has lost nearly $4 billion from the sale of its services, and it alleges that the losses are likely to be even greater in the future.

Alibaba has denied the allegations, saying it has consistently demonstrated that it takes the health of its customers very seriously.

It also claims that the lawsuits are baseless and the court should dismiss the case.

The lawsuit accuses Alibaba of “continually seeking to prevent competitors from gaining access to its own marketplace for their own personal health information.”

The suit, filed in the US District Court for the Southern District of California, was filed on behalf of consumers in California, Nevada, Arizona, Utah and New Mexico.

In its suit, Alibaba claims the class members suffered losses of $1.2 billion from 2014 to 2019 and $4.6 billion in 2020 and 2021.

Albatross health information The lawsuit alleges that Alibaba has been involved in an “all-out assault” on rivals in the health care industry, claiming that its “anti-viral drugs” have led to the loss of at least $6 billion to the health industry.

The company also claims it has been unfairly targeted by competitors in the healthcare industry, including health insurance companies.

In a statement provided to ABC News, Alibaba said it is a leader in health information and data services.

“Alibaba is a trusted and trusted partner of many health care providers around the world,” the statement said.

“The fact that the plaintiffs have lost their ability to sell and buy health information is disappointing.”

The company’s lawsuit claims that Alibaba’s anti-counterfeiting measures are so effective that they “have prevented millions of legitimate businesses and individuals from gaining control over counterfeit health information in the first place.”

The lawsuit alleges the company has lost billions of dollars due to its actions.

The plaintiffs are also seeking $5 billion in damages, as well as damages from Alibaba for “damages and costs to its reputation” and to “damage to the business reputation and reputation of the plaintiffs and the health-care industry in general.”ABC News’ Daniel Nussbaum and Andrew Gombert contributed to this report.ABC News first reported the lawsuit on Monday.